Can ResMed Beat These Numbers?
ResMed (NYS: RMD) is expected to report Q4 earnings on Aug. 1. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ResMed's revenues will grow 10.8% and EPS will grow 14.8%.
The average estimate for revenue is $412.2 million. On the bottom line, the average EPS estimate is $0.62.
Last quarter, ResMed reported revenue of $383.6 million. GAAP reported sales were 9.9% higher than the prior-year quarter's $349.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.59. GAAP EPS of $0.58 for Q3 were 32% higher than the prior-year quarter's $0.44 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 62.4%, 210 basis points better than the prior-year quarter. Operating margin was 25.1%, 320 basis points better than the prior-year quarter. Net margin was 22.1%, 360 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.51 billion. The average EPS estimate is $2.27.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 193 members out of 209 rating the stock outperform, and 16 members rating it underperform. Among 68 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 64 give ResMed a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is outperform, with an average price target of $45.46.
Is ResMed the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add ResMed to My Watchlist.
The article Can ResMed Beat These Numbers? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.